Menu ×


Sterile Injectable Drugs Market Segmentation by Type (Small Molecule, and Large Molecule); by Drug Class (Insulin, Hormones, Vaccines, Peptide Antibiotic, Cytokines, and Others); by Application (Pain, Infections, Autoimmune Disease, Diabetes, Cardiovascular Diseases, and Others); and by Distribution Channel (Hospitals, Pharmacy, Ambulatory Surgical Centers, and Others)– Global Demand Analysis & Opportunity Outlook 2029

  • Text Size:

Extensive insights into the Growth of Sterile Injectable Drugs Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


·  December 19, 2018: Pfizer Inc and GlaxoSmithKline plc announced to join hands to form new consumer healthcare joint venture, on a global level.

·  June 23, 2018: Amgen announced the launch of drug Repatha (evolocumab) that helps to significantly reduced cholesterol in Type 2 diabetes patients.

·  July 07, 2020: GlaxoSmithKline plc (GSK) and Medicago announced their collaboration to develop vaccine for COVID-19

Global Sterile Injectable Drugs Market Highlights over 2020-2029

The global sterile injectable drugs market is estimated to grow at a considerable CAGR over the forecast period, i.e., 2021–2029. The growth of the market can be attributed to the rising prevalence of chronic diseases around the globe, along with rising health awareness among people and authorities. Government initiatives to curb spread of diseases in the form of investment in healthcare sector, and vaccination drives, among others, is estimated to boost the market growth. Moreover, the COVID-19 pandemic has emphasized the need for more efficient healthcare system, R&D activities for novel treatment methods, and quicker development and approval of drugs, on a global level, which is estimated to boost the market growth significantly in the upcoming years.

Sterile Injectable Drugs Market

The global sterile injectable drugs market is segmented by drug class into insulin, hormones, vaccines, peptide antibiotic, cytokines, and others, out of which, the vaccines segment is anticipated to hold the largest share in the market during the forecast period on account of escalating demand for vaccines for various infectious diseases, with respect to the spread of coronavirus, and other viral and bacterial diseases, including smallpox, measles, rubella, polio, and others. The insulin segment is also anticipated to witness major market share over the forecast period, owing to the rising cases of type 1 and type 2 diabetes. According to statistics by the World Health Organization (WHO), in 2019, diabetes caused an estimated 1.5 million deaths, all over the globe. Moreover, premature mortality rate from diabetes increased 5% from 2000 to 2016. On the basis of distribution channel, the market is segmented into hospitals, pharmacy, ambulatory surgical centers, and others. Out of these, the hospitals segment is anticipated to witness highest CAGR over the forecast period on the back of higher patient pool, ease of availability, and greater credibility of hospitals over general pharmacies. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Sterile Injectable Drugs Market Regional Synopsis

Regionally, the global sterile injectable drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is estimated to witness largest share over the forecast period on the back of high investment in healthcare sector, along with increasing medical R&D activities in the region. According to the data by the World Bank, per capita healthcare expenditure in the North America amounted to USD 10,050.279, in 2018. The market in the Asia Pacific is estimated to witness a noteworthy growth during the forecast period, owing to the improving healthcare sector backed by rising disposable income and economic development in the region.

Global Sterile Injectable Drugs Market

The global sterile injectable drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global sterile injectable drugs market includes the following segments:

By Type

  • Small Molecule
  • Large Molecule

By Drug Class

  • Insulin
  • Hormones
  • Vaccines
  • Peptide Antibiotics
  • Cytokines
  • Others

By Application

  • Pain
  • Infections
  • Autoimmune Diseases
  • Diabetes
  • Cardiovascular Diseases
  • Other

By Distribution Channel

  • Hospitals
  • Pharmacy
  • Ambulatory Surgical Centers
  • Others

Growth Drivers

  • Rising Prevalence of Diseases
  • Increasing Need for Vaccines amidst COVID-19 Pandemic


  • Long Time Taken for the Approval of Drugs

Top Featured Companies Dominating the Market

  • Sanofi-aventis Groupe
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Progenity, Inc.
  • Johnson & Johnson Services, Inc.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved